

PII: S0040-4039(97)10501-9

SPONGISTATIN SYNTHETIC STUDIES. 3. CONSTRUCTION OF THE C(1-17) SPIROKETAL

Amos B. Smith, III,* Qiyan Lin, Kiyoshi Nakayama, Armen M. Boldi, Christopher S. Brook, Mark D. McBriar, William H. Moser, Masao Sobukawa, and Linghang Zhuang

Department of Chemistry, Laboratory for Research on the Structure of Matter, and Monell Chemical Senses Center, University of Pennsylvania, Philadelphia, PA 19104, U.S.A.

Summary: A convergent synthesis of the C(1-17) AB-ring subunit of the spongistatins, exceedingly scarce and highly antimitotic polyether macrolides, has been achieved via a one-flask dithiane bisalkylation, stereocontrolled spiroketalization, and Julia sulfone coupling/methylenation. © 1997 Elsevier Science Ltd.

In the first two Letters in this series,¹ we described considerable progress toward the total synthesis of the spongistatins (e.g., 1 and 2, Scheme 1), a family of rare and architecturally novel sponge metabolites with unprecedented antitumor activity.² Herein we report the assembly of the C(1-17) AB-ring spiroketal subunit 3.

Scheme I



Initial retrosynthetic disconnection of 3 generated the iodo spiroketal 4 and sulfone 5 (Scheme I). The AB-ring spiro moiety of the spongistatins is stabilized by two anomeric interactions;³ MM2 calculations⁴ confirmed that the requisite spiro configuration in 4 is thermodynamically favored. Accordingly, the acyclic dithiane 6 was envisioned as a suitable precursor. The sulfone fragment 5 was expected to derive from aldehyde 7^5 via coupling with (*E*)-crotylborane 8^6 according to the procedure of Roush.⁶

Analysis of dithiane **6** (Scheme II) revealed another opportunity to exploit the one-pot unsymmetrical bisalkylation of 2-TBS-1,3-dithiane (**10**), developed in these laboratories⁷ and advantageously employed in our synthesis of the spongistatin AB-ring spiroketal.¹ This

AB-ring spiroketal.¹ This tactic concisely affords polyol chains with rigorous stereochemical control and differentiation of the hydroxyl groups. Application to the ketalization substrate 6 required



 $\Rightarrow \boxed{\begin{array}{c} TESO \\ 1 \\ BPSO \\ 9 \end{array}} \begin{array}{c} & & & & \\$

the C(1-6) and C(8-12) epoxides 9 and 11 as coupling partners.8

Construction of **9** began with known aldehyde **12**⁹ (Scheme III), available in two steps from **1**,3-propanediol. Addition of allyl(diisopinocampheyl)borane¹⁰ provided allylic alcohol (+)-**13**¹¹ in 98% yield and 84% ee (Mosher analysis).¹²

Following acylation with *t*-Boc anhydride, our modification¹³ of the Bartlett carbonate cyclization¹⁴ (IBr, toluene, -80 °C) generated iodo carbonate (+)-14¹¹ with 27:1 diastereoselectivity. Treatment of the crude mixture with K₂CO₃



in methanol furnished epoxy alcohol (+)-15¹¹ (60% yield, two steps). Removal of the minor diastereomer by flash chromatography and silvlation (TESCI, TMEDA, DMF, 96%) gave the C(1-6) building block (-)-9.¹¹

Epoxide (+)-11 was efficiently prepared from the isopropylidene derivative of L-glyceraldehyde [(-)-16;¹⁵ Scheme IV]. The two-step method of Fukumoto¹⁶ (i.e., Wittig olefination followed by DIBAL reduction) furnished allylic alcohol (-)-17¹¹ in excellent yield. Despite a mismatched reagent-substrate pair,¹⁷ Sharpless asymmetric epoxidation¹⁸ provided (+)-18¹¹ as an acceptable 4.2:1 mixture of diastereomers (88% yield) on a 50-g scale. After separation via flash chromatography, chelation-controlled reduction¹⁹ of (+)-18¹¹ [LiBH₄, Ti(O-*i*-Pr)₄, CH₂Cl₂, -20 °C; 88%] and a modified Kishi cyclization²⁰ of the resultant diol (tosylimidazole, NaH; 93%) completed the synthesis of the C(8-12) epoxide (+)-11.¹¹

Scheme IV



The unsymmetrical bisalkylation of dithiane 10 with epoxides (-)-9 and (+)-11 was carried out via the protocol we described earlier,⁷ providing the desired coupling product (-)-19¹¹ in 65% yield (Scheme V). With the requisite polyol in hand, we turned next to the generation of the AB-ring spiroketal (Scheme VI). Exposure of dithiane (-)-19 to TFA/CH₂Cl₂/H₂O (3:10:10) at 0 °C removed both

the TES and isopropylidene groups (90% yield). Selective tosylation of the primary alcohol (TsCl, DMAP, CH₂Cl₂; 88%) then provided triol (+)-6.¹¹ Treatment of the dithiane with mercuric perchlorate in aqueous acetonitrile (1:9, calcium carbonate buffer) afforded a separable 26:1 mixture of spiroketals (-)-21¹¹ and (-)-20¹¹ in 81% yield.²¹ The minor isomer (-)-20 readily isomerized to (-)-21 (CSA, CH₂Cl₂; 77%); the relative stereochemistry



of the spiro center was confirmed by ¹H NOE studies. Protection of the secondary alcohol as a TES ether and introduction of the primary iodide (Lil, imid., DMF; 96%, two steps) generated the C(1-12) fragment (-)-4.¹¹

Scheme VI



Sulfone 5 derived from the known aldehyde (-)-7⁵ (Scheme VII). Roush asymmetric crotylboration⁶ with 8 (74% yield, 18:1 selectivity) followed by desilylation (TBAF, THF; 94%) and acetal formation (3,4-dimethoxybenzaldehyde, TsOH,

CH₂Cl₂; 94%) furnished (+)-22.¹¹ Reductive cleavage of the acetal (DIBAL, CH₂Cl₂, 0 °C; 91% yield), tosylation of the resultant primary alcohol (TsCl, Et₃N, DMAP; 98%), and coupling with PhSO₂Na (87%) then provided sulfone (-)-23.¹¹ The dithiane moiety was introduced in 61% overall yield via oxidative cleavage of the terminal olefin and thioacetalization. The latter procedure also removed the 3,4-dimethoxybenzyl ether; reprotection (TESOTf, 2,6-lut, CH₂Cl₂; 80%) afforded the C(13-17) segment (+)-5.¹¹



Alkylation of the lithio derivative of sulfone (+)-5 with iodide (-)-4 proceeded smoothly (76% yield, Scheme VIII). Julia methylenation (*n*-BuLi, THF, ICH₂MgCl; 23%),²² used earlier to introduce the C(45) exomethylene moiety,¹ then generated (+)-3,¹¹ the C(1-17) AB-ring spiroketal advanced intermediate.

In summary, we have completed the first synthesis of the C(1-17) subunit of the spongistatins, exploiting a one-pot dithiane unsymmetrical bisalkylation, a stereocontrolled spiroketalization, and a Julia sulfone coupling/methylenation protocol, the latter to unite (-)-4 and Scheme VIII



(+)-5. With the ready availability of the C(18-28) and C(29-48) advanced intermediates, described in the first two Letters in this series, completion of the spongistatin synthetic venture is under active investigation.

Acknowledgments. We thank the National Institutes of Health (National Cancer Institute, grant CA-70329), SmithKline Beecham, Dupont Merck Pharmaceutical Co., and Zeneca Inc. for financial support. A. M. B., C. S. B., and W. H. M. gratefully acknowledge the award of National Institutes of Health Postdoctoral Fellowships.

REFERENCES AND NOTES

- 1. Parts 1 and 2: preceding Letters in this issue.
- For leading references, see: a) Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R.; Schmidt, J. M.; Hooper, J. N. A. J. Org. Chem. 1993, 58, 1302-1304. b) Bai, R.; Taylor, G. F.; Cichacz, Z. A.; Herald, C. L.; Kepler, J. A.; Pettit, G. R.; Harnel, E. Biochemistry 1995, 34, 9714-9721.
- 3. Perron, F.; Albizati, K. F. Chem. Rev. 1989, 89, 1617-1661.
- The 1987 version of the MM2 force field was employed in conjunction with the MacroModel program (version 3.1): a) Bowen, J. P.; Pathiaseril, A.; Profeta, S., Jr.; Allinger, N. L. *J. Org. Chem.* 1987, *52*, 5162-5166. Allinger, N. L. *J. Am. Chem. Soc.* 1977, *99*, 8127-8134. b) Still, W. C.; Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Lipton, M.; Liskamp, R.; Chang, G.; Hendrickson, T.; DeGunst, F.; Hasel, W. Department of Chemistry, Columbia University, New York, NY 10027.
- 5. Roush, W. R.; VanNieuwenhze, M. S. J. Am. Chem. Soc. 1994, 116, 8536-8543.
- 6. Roush, W. R.; Ando, K.; Powers, D. B.; Palkowitz, A. D.; Halterman, R. L. J. Am. Chem. Soc. 1990, 112, 6339-6348.
- 7. Smith, A. B., III; Boldi, A. M. J. Am. Chem. Soc. 1997, 119, 6925-6926.
- 8. We have also developed an effective stepwise approach to (+)-6:



- 9. Boeckman, R. K., Jr.; Charette, A. B.; Asberon, T.; Johnston, B. H. J. Am. Chem. Soc. 1987, 109, 7553-7555.
- a) Brown, H. C.; Bhat, K. S.; Randad, R. S. J. Org. Chem. 1987, 52, 319-320. b) Brown, H. C.; Bhat, K. S.; Randad, R. S. J. Org. Chem. 1987, 52, 3701-3702.
- The structure assigned to each new compound is in accord with its infrared, 500-MHz ¹H NMR, and 125-MHz ¹³C NMR spectra, as well as appropriate parent ion identification by high resolution mass spectrometry.
- Dale, J. A.; Mosher, H. S. *J. Am. Chem. Soc.* **1973**, *95*, 512-519. Sullivan, G. R.; Dale, J. A.; Mosher, H. S. *J. Org. Chem.* **1973**, *38*, 2143-2147. Also see: Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. J. Am. Chem. Soc. **1991**, *113*, 4092-4096.
- 13. Duan, J. J.-W.; Smith, A. B., III J. Org. Chem. 1993, 58, 3703-3711.
- 14. Bartiett, P. A.; Meadows, J. D.; Brown, E. G.; Morimoto, A.; Jernstedt, K. K. J. Org. Chem. 1982, 47, 4013-4018.
- 15. Hubschwerlen, C.; Specklin, J.-L.; Higelin, J. Org. Synth. 1995, 72, 1-5.
- 16. Nemoto, H.; Satoh, A.; Ando, M.; Fukumoto, K. J. Chem. Soc., Perkin Trans. / 1991, 1309-1314.
- 17. Masamune, S.; Choy, W.; Petersen, J. S.; Sita, L. R. Angew. Chem., Int. Ed. Engl. 1985, 24, 1-30.
- 18. Katsuki, T.; Sharpless, K. B. J. Am. Chem. Soc. 1980, 102, 5974-5976.
- 19. Dai, L.-X.; Lou, B.-L.; Zhang, Y.-Z.; Guo, G.-Z. Tetrahedron Lett. 1986, 27, 4343-4346.
- 20. Hong, C. Y.; Kishi, Y. J. Am. Chem. Soc. 1991, 113, 9693-9694.
- While our manuscript was in preparation, a related spiroketalization was described: Paquette, L. A.; Zuev, D. Tetrahedron Lett. 1997, 38, 5115-5118. See also: Claffey, M. M.; Heathcock, C. H. J. Org. Chem. 1996, 61, 7646-7647. Paterson, I.; Oballa, R. M.; Norcross, R. D. Tetrahedron Lett. 1996, 37, 8581-8584.
- De Lima, C.; Julia, M.; Verpeaux, J.-N. Synlett 1992, 133-134. Also see: Romo, D.; Meyer, S. D.; Johnson, D. D.; Schreiber, S. L. J. Am. Chem. Soc. 1993, 115, 7906-7907.

(Received in USA 12 August 1997; revised 29 August 1997; accepted 24 October 1997)